Previous Article | Next Article ![]()
Journal of Virology, August 2000, p. 6946-6952, Vol. 74, No. 15
Division of Viral Products, Center for
Biologics Evaluation and Research, Food and Drug
Administration,1 and Laboratory of
Host Defenses, National Institute of Allergy and Infectious
Diseases, National Institutes of Health,2
Bethesda, Maryland 20892
Received 7 February 2000/Accepted 4 May 2000
To determine whether human immunodeficiency virus type 1 (HIV-1)
coreceptors besides CXCR4 and CCR5 are involved in HIV-1 infection of
the thymus, we focused on CCR8, a receptor for the chemokine I-309,
because of its high expression in the thymus. Similar levels of CCR8
mRNA were detected in immature and mature primary human thymocytes.
Consistent with this, [125I]I-309 was shown to bind
specifically and with similar affinity to the surface of immature and
mature human thymocytes. Fusion of human thymocytes with cells
expressing HIV-1 X4 or X4R5 envelope glycoprotein was inhibited by
I-309 in a dose-dependent manner. In addition, I-309 partially
inhibited productive infection of human thymocytes by X4, R5, and X4R5
HIV-1 strains. Our data provide the first evidence that CCR8 functions
as an HIV-1 coreceptor on primary human cells and suggest that CCR8 may
contribute to HIV-1-induced thymic pathogenesis.
0022-538X/00/$04.00+0
CCR8 on Human Thymocytes Functions as a Human
Immunodeficiency Virus Type 1 Coreceptor

*
Corresponding author. Mailing address: Division of
Viral Products, FDA, CBER, Bldg. 29B, 8800 Rockville Pike, Bethesda, MD 20892. Phone: (301) 827-0736. Fax: (301) 496-1810. E-mail:
zaitseva{at}cber.fda.gov.
Present address: Department of Retrovirology, Walter Reed Army
Institute of Research, Rockville, MD 20850.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|